You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Solving Sepsis: Early Identification and Prompt Management Using Machine Learning
SBC: Cohere-Med, Inc. Topic: 300Abstract This fast-track STTR application proposes to enhance, validate, and scale Sepsis Watch, a deep learning sepsis detection and management system built using data from the Emergency Department (ED) Duke University Hospital (DUH). The proposal will extend and enhance Sepsis Watch to EDs, general inpatient wards, and intensive care unit (ICU) settings across multiple health systems in the Unit ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes
SBC: VALA SCIENCES, INC. Topic: NHLBICardiotoxicity is a leading cause of drug discovery attrition across all of preclinical and clinical drug discovery. While the FDA and the Comprehensive in vitro Proarrhythmia Assay initiative (CiPA) are focused primarily on predicting proarrhythmic effects, drug attrition due to cardiomyopathy, or primary cardiac cytotoxicity, may be even more prevalent, is typically currently only carried out vi ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Automated Mental Health Referral System
SBC: MiResource, Inc. Topic: 104This proposal addresses a significant barrier to obtaining treatment for college-ageyouth with mental disorders. Many college-age youth with impairing mental disordersremain untreated because of concerns about stigma and privacy, inconvenience and wait times, andbecause universities are often unable to service all such students. Also, of critical importance,when referral for treatment is implement ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A digital tool for monitoring speech decline in ALS
SBC: MODALITY.AI , INC Topic: NIDCDPROJECT SUMMARY Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease resulting in the progressive loss of limb, trunk, and head and neck (bulbar) motor function and is the most common adult-onset motor neuron disease. The disease is characterized by significant across-patient heterogeneity in the onset region and in pattern and progression rate, making early and accurate diagno ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Endovascular ChemoFilter to Reduce Doxorubicin Toxicity during Intra-Arterial Chemotherapy
SBC: FILTRO MEDICAL INC. Topic: 102PROJECT SUMMARYDosing of chemotherapeutics is limited by systemic toxic side effects. We are developing a new class of image- guided temporarily deployable, endovascular catheter-based medical devices that selectively remove specific drugs from the blood stream to reduce systemic toxicities. The proposed ChemoFilters incorporate specialized materials that bind target drugs in situ through a variet ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease
SBC: Hillhurst Biopharmaceuticals, Inc. Topic: NHLBIPROJECT SUMMARY/ABSTRACT The goal of the proposed project is to evaluate the clinical potential of HBI-002, a novel oral low dose carbon monoxide (CO) drug product, that enables the use of low dose CO to prevent Vaso-Occlusive Crises (VOCs) in Sickle Cell Disease (SCD). Numerous studies, both preclinical and clinical, demonstrate that CO has dual mechanisms of action including anti-sickling and an ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A silicon nanopore membrane blood filter enabling anticoagulant free continuous renal replacement therapy for acute kidney injury
SBC: Silicon Kidney Topic: 400Project Summary Acute Kidney Injury (AKI) commonly occurs in critically ill patients in the ICU. Patients with severe AKI often require continuous renal replacement therapy (CRRT) because it enables hemodynamic stability and better volume control. Anticoagulation therapy is frequently used to keep the CRRT circuit (especially the blood filter) from clotting as many critically ill patients are prot ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel peptide for enhancing diabetic wound healing
SBC: SCARLESS LABORATORIES INC Topic: 200PROJECT SUMMARY/ABSTRACT Diabetes Mellitus (DM), a metabolic disorder characterized by defective insulin signaling and elevated blood glucose, has become a public health epidemic with half of the US population diagnosed with either DM or pre- diabetes. One of the most common and devastating sequelae of uncontrolled DM is the development of chronic non-healing wounds. An estimated 25% of diabetic p ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD
SBC: ACURASTEM INC Topic: NIADevelopment of a SYF2 antisense oligonucleotide treatment for ALS and FTD Project Summary Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are complex diseases that result from many diverse genetic etiologies. Although therapeutic strategies that target specific causal mutations (e.g. C9ORF72 antisense oligonucleotides (ASOs)) may prove effective against individual forms of AL ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Humanized monoclonal antibodies to treat mucormycosis
SBC: VITALEX BIOSCIENCES, LLC Topic: NIAIDMucormycosis, caused by Mucorales fungi, is a life-threatening infection that occurs in patients immunocom- promised by diabetic ketoacidosis, neutropenia, corticosteroid use, and/or increased serum iron. Because of the rising prevalence of mucormycosis risk factors, the incidence of the infection has risen. The increased number of mucormycosis cases is highlighted by the recent epidemic seen amon ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health